Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

PCI Biotech: Second quarter and first half year 2016 results

PCI Biotech Holding
Posted on: 30 Aug 16

Oslo, 30 August 2016.

Please find enclosed the financial report and presentation for second quarter 2016.


  • Granted Orphan Drug Designation of fimaporfin for treatment of bile duct cancer in EU
  • Commissioned independent expert evaluation of the early promising response data - results expected Q3 2016
  • Lancet Oncology publication of the fimaporfin (Amphinex) first-in-man phase I study - with independent expert commentary
  • fima Vacc ready for clinical validation - a major milestone towards potential commercialization
  • Initiated first research collaboration with commercial entity for fima Vacc

A presentation will be held today, Tuesday 30 August 2016, at Oslo Cancer Cluster Innovation Park.

Time: Tuesday August 30 2016, 09.00-10.00 hrs.
Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo.

Kind regards,
Per Walday
Mobil: +47 917 93 429

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. PCI Biotech Q2 2016 Report
PCI Biotech Q2 2016 Presentation

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: PCI Biotech Holding via GlobeNewswire

Last updated on: 31/08/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.